EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates

Yihui Jin, Lili Qu, Xin Gao, Xiao Qi, Dongmin Zhao, Lu Ga, Yan Zhao, Guodong Liang, Yunfeng Xiao, Yuheng Ma

Viruses · 02.07.2026 · 18 (7) · 737

DOI: 10.3390/v18070737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 02.07.2026. Verfasst von Yihui Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 0101…. Hauptthemen laut MEDLINE: Triazoles, SARS-CoV-2, Antiviral Agents, Peptides. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation Project of Inner Mongolia Autonomous Region of China, State Key Laboratory of Natural and Biomimetic Drugs, Inner Mongolia Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the current treatment limitations—particularly the emergence of drug resistance and the reduced efficacy of some existing drugs against new variants—highlight the need for novel antiviral strategies with novel action mechanisms. Fusion inhibitors that disrupt six-helix bundle (6-HB) formation during viral entry represent a promising approach. Posaconazole, an antifungal agent, has been identified as a weak fusion inhibitor, but suffers from poor membrane permeability and modest activity. This study aimed to enhance its antiviral potency by conjugating it with cell-penetrating polyarginine peptides and to investigate the mechanism of action.

Methods

A series of posaconazole-polyarginine conjugates were synthesized via click chemistry. Antiviral activity was evaluated using pseudotyped SARS-CoV-2 Omicron XDV in HEK293T cells. Mechanisms were investigated by circular dichroism, native PAGE, size-exclusion HPLC, molecular docking, and isothermal titration calorimetry. Metabolic stability was assessed using hepatic microsomes.

Results

Posa-R8 exhibited potent antiviral activity comparable to the clinical candidate EK1, with minimal cytotoxicity. Mechanistic studies confirmed that Posa-R8 binds the HR2 region of the spike protein, disrupts 6-HB formation, and inhibits membrane fusion. It also showed strong lipid bilayer affinity and improved phase I metabolic stability over EK1.

Conclusions

Polyarginine conjugation enhances the membrane-binding affinity and antiviral efficacy of posaconazole. Posa-R8 represents a promising lead for developing next-generation SARS-CoV-2 fusion inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesSARS-CoV-2Antiviral AgentsPeptidesVirus InternalizationViral Fusion Protein InhibitorsHumansHEK293 CellsMolecular Docking SimulationCOVID-19 Drug Treatment

Stichwörter der Autor:innen

SARS-CoV-2conjugatesfusion inhibitorspolyarginineposaconazole

Substanzen

TriazolesposaconazolepolyarginineAntiviral AgentsPeptidesViral Fusion Protein Inhibitors

Autor:innen und Institutionen

  • Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China.
  • Department of Pharmacy, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010030, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China.
  • Peptide Drugs Research and Development Center, Zhen-Xiang Technology Co., Ltd., Hohhot 011500, China.

Förderung

  • Natural Science Foundation Project of Inner Mongolia Autonomous Region of China
  • State Key Laboratory of Natural and Biomimetic Drugs
  • Inner Mongolia Medical University
  • Ph.D. Scientific Research Foundation of Inner Mongolia Medical University
  • Inner Mongolia Medical University Student Innovation and Entrepreneurship Project

Zitieren

APA

Jin, Y., Qu, L., Gao, X., Qi, X., Zhao, D., Ga, L., Zhao, Y., Liang, G., Xiao, Y., & Ma, Y. (2026). Discovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates. Viruses, 18(7), 737. https://doi.org/10.3390/v18070737

Vancouver

Jin Y, Qu L, Gao X, Qi X, Zhao D, Ga L, et al. Discovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates. Viruses. 2026;18(7):737. doi:10.3390/v18070737

BibTeX
@article{Jin2026,
  author = {Jin, Yihui and Qu, Lili and Gao, Xin and Qi, Xiao and Zhao, Dongmin and Ga, Lu and Zhao, Yan and Liang, Guodong and Xiao, Yunfeng and Ma, Yuheng},
  title = {Discovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {737},
  doi = {10.3390/v18070737}
}
Kostenlos starten →